Castle Biosciences (CSTL) vs Danaher (DHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Castle Biosciences (CSTL) has outperformed Danaher (DHR) over the past year, gaining 44.0% versus a gain of 4.7%. Over five years, DHR leads with a -18.2% price change compared with -48.1% for CSTL. Danaher is the larger company by market cap ($151.58 billion vs $1.01 billion), about 149.5 times the size.
Danaher pays a dividend yielding 0.67%, while Castle Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSTL | DHR |
|---|---|---|
| Share price | $33.20 | $215.63 |
| Market cap | $1.01B | $151.58B |
| 1-day change | +0.59% | -1.31% |
| YTD return | -15.17% | -4.56% |
| 1-year return | +43.98% | +4.66% |
| 5-year return | -48.10% | -18.22% |
| P/E ratio (TTM) | — | 38.44 |
| Forward P/E | — | 23.19 |
| EPS (TTM) | $-0.64 | $5.61 |
| Dividend yield | 0.00% | 0.67% |
| Annual dividend | $0.00 | $1.44 |
| Revenue (latest FY) | — | $24.57B |
| Revenue growth (YoY) | — | +2.90% |
| Net income (latest FY) | — | $3.61B |
| Gross margin | — | 59.11% |
| Operating margin | — | 19.09% |
| Net margin | — | 14.71% |
| 52-week high | $44.28 | $242.80 |
| 52-week low | $17.72 | $160.93 |
| Distance from 52-week high | -25.03% | -11.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +35.89% | +10.86% |
| Average volume | 401.17K | 4.70M |
| Shares outstanding | 30.55M | 702.99M |
| Employees | 1,002 | 58,000 |
| Sector | Health Care | Industrials |
| Industry | Medical Specialities | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Danaher is about 149.5 times larger than Castle Biosciences by market value ($151.58B vs $1.01B).
- CSTL has outperformed DHR by 39.3 percentage points over the past year.
- The two companies sit in different sectors: Castle Biosciences in Health Care and Danaher in Industrials.
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,002 employees
About Danaher
DHR stock →Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Industrials · Industrial Machinery/Components · 58,000 employees
CSTL vs DHR FAQ
Which is bigger, Castle Biosciences or Danaher?
Danaher (DHR) is larger, with a market capitalization of $151.58B compared with $1.01B for Castle Biosciences (CSTL).
Which stock has performed better over the past year, CSTL or DHR?
CSTL returned +43.98% over the past 12 months, compared with +4.66% for DHR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Castle Biosciences or Danaher?
Danaher pays a dividend yielding 0.67%, while Castle Biosciences does not currently pay a regular dividend.
Are Castle Biosciences and Danaher in the same industry?
No. Castle Biosciences is in the Health Care sector, while Danaher is in Industrials.